{"id":55269,"date":"2023-03-28T17:04:12","date_gmt":"2023-03-28T15:04:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/"},"modified":"2023-03-28T17:04:12","modified_gmt":"2023-03-28T15:04:12","slug":"andrew-miller-joins-elucid-as-chief-technology-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/","title":{"rendered":"Andrew Miller Joins Elucid as Chief Technology Officer"},"content":{"rendered":"
\n

\nGrowth-focused leader will help bring the company\u2019s AI-powered <\/i><\/b>cardiovascular technology to market<\/i><\/b>\n<\/p>\n

BOSTON–(BUSINESS WIRE)–Elucid, Inc.<\/a>, a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and oversee the engineering team\u2019s execution. Elucid\u2019s software<\/a> is the only FDA-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope and establishing a histologic ground truth. Elucid is also pursuing an indication for FFRCT, <\/sub>uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe\u2019re thrilled to welcome Andrew as CTO. He has an incredible technological skillset and proven track record in building high-performing technology teams across numerous successful organizations throughout his career,\u201d said Blake Richards, chief executive officer, Elucid. \u201cA true thought leader, his expertise executing vision and growing organizations will help propel Elucid as we grow commercially and realize the next phase of our mission to provide comprehensive and accurate clinical insights that enable unprecedented precision healthcare for vascular disease.\u201d\n<\/p>\n

\nMiller is a health technology veteran with an acumen for transforming startups and growth-stage companies into mature organizations. His proven history of building diverse, high-performing organizations has led to profitable business and acquisition. He joins Elucid from Engooden Health, where he served as CTO and chief information security officer, responsible for delivery of technology solutions and infrastructure supporting the SaaS and service-based organization in its mission to redefine chronic care management. Prior to his leadership role at Engooden, Miller served as vice president of engineering for Curaspan, a naviHealth company. Previously, he held roles at Oracle as a senior leader in its Health Sciences division, and Phase Forward, among others.\n<\/p>\n

\nMiller joins recent hires Dr. Todd Villines<\/a>, chief medical officer, and Scott Burger<\/a>, chief commercial officer, on Elucid\u2019s leadership team.\n<\/p>\n

\n\u201cElucid offers an exciting opportunity that allows me to leverage my experience and skills to work with the talented team already assembled to achieve our goals,\u201d said Miller. \u201cAlong with Blake and the rest of the leadership team, I am ready to roll up my sleeves and ensure the company\u2019s groundbreaking technology is developed and advanced in a way that fits seamlessly into physician workflow in the most elegant and useful way possible to help solve one of the biggest challenges facing healthcare today.\u201d\n<\/p>\n

\nAbout Elucid<\/i><\/b>\n<\/p>\n

\nElucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software is designed to deeply understand the root cause of cardiovascular disease. Elucid’s plaque analysis software is powered by PlaqueIQ, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue samples by renowned pathologists. Elucid is also pursuing an indication for FFRCT<\/sub>, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia. PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid plaque analysis software is available for commercial use in the U.S. and South Korea. For more information, visit elucid.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSam Choinski
\n
Pazanga Health Communications
\n
(860) 301-5058
\n
schoinski@pazangahealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Growth-focused leader will help bring the company\u2019s AI-powered cardiovascular technology to market BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and oversee the engineering team\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55269","6":"format-standard","7":"category-industry"},"yoast_head":"\nAndrew Miller Joins Elucid as Chief Technology Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andrew Miller Joins Elucid as Chief Technology Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Growth-focused leader will help bring the company\u2019s AI-powered cardiovascular technology to market BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and oversee the engineering team\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T15:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230328005307\/en\/1748608\/21\/Elucid-Logo-CMYK_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Andrew Miller Joins Elucid as Chief Technology Officer\",\"datePublished\":\"2023-03-28T15:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005307\\\/en\\\/1748608\\\/21\\\/Elucid-Logo-CMYK_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/\",\"name\":\"Andrew Miller Joins Elucid as Chief Technology Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005307\\\/en\\\/1748608\\\/21\\\/Elucid-Logo-CMYK_copy.jpg\",\"datePublished\":\"2023-03-28T15:04:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005307\\\/en\\\/1748608\\\/21\\\/Elucid-Logo-CMYK_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005307\\\/en\\\/1748608\\\/21\\\/Elucid-Logo-CMYK_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/andrew-miller-joins-elucid-as-chief-technology-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andrew Miller Joins Elucid as Chief Technology Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andrew Miller Joins Elucid as Chief Technology Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/","og_locale":"en_US","og_type":"article","og_title":"Andrew Miller Joins Elucid as Chief Technology Officer - Pharma Trend","og_description":"Growth-focused leader will help bring the company\u2019s AI-powered cardiovascular technology to market BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and oversee the engineering team\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T15:04:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230328005307\/en\/1748608\/21\/Elucid-Logo-CMYK_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Andrew Miller Joins Elucid as Chief Technology Officer","datePublished":"2023-03-28T15:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/"},"wordCount":567,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005307\/en\/1748608\/21\/Elucid-Logo-CMYK_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/","url":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/","name":"Andrew Miller Joins Elucid as Chief Technology Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005307\/en\/1748608\/21\/Elucid-Logo-CMYK_copy.jpg","datePublished":"2023-03-28T15:04:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230328005307\/en\/1748608\/21\/Elucid-Logo-CMYK_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230328005307\/en\/1748608\/21\/Elucid-Logo-CMYK_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/andrew-miller-joins-elucid-as-chief-technology-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andrew Miller Joins Elucid as Chief Technology Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55269"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55269\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}